Status:

RECRUITING

A Single-dose Study to Evaluate the Safety, Tolerability, Drug Levels, and Relative Biological Availability of Alternate Formulations of BMS-986460 in Healthy Adult Male Participants

Lead Sponsor:

Bristol-Myers Squibb

Conditions:

Healthy Volunteers

Eligibility:

MALE

18-60 years

Phase:

PHASE1

Brief Summary

The purpose of this study is to assess the safety, tolerability, drug levels, and relative bioavailability of alternate formulations of BMS-986460 in healthy adult male participants.

Eligibility Criteria

Inclusion

  • Inclusion Criteria
  • Participants must be healthy as determined by no clinically significant deviation from normal in medical history, physical examination, vital signs, 12-lead ECGs, echocardiogram or clinical laboratory assessments, as determined by the investigator.
  • Participants must have a Body mass index (BMI) between 18.0 and 35.0 kilograms/meter square (kg/m2), inclusive.
  • Male participants who are sexually active with individuals of childbearing potential (IOCBP) must agree to follow instructions for methods of contraception.
  • Exclusion Criteria:
  • Participants with prior exposure to BMS-986460 or with a prior history of heart failure, ischemic heart diseases, clinically significant cardiac arrythmias, or long QT syndrome are excluded.
  • Participants with left ventricular ejection fraction (≤ 50%) at screening are excluded.
  • Participants with history of anaphylactic reactions are excluded.
  • Participants with current or recent (within 3 months of intervention administration) gastrointestinal disease that, in the opinion of the investigator, could affect the absorption of study intervention are excluded.
  • Participants with history of Gilbert's syndrome are excluded.
  • Other protocol-defined Inclusion/Exclusion criteria apply.

Exclusion

    Key Trial Info

    Start Date :

    March 19 2025

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    December 17 2025

    Estimated Enrollment :

    56 Patients enrolled

    Trial Details

    Trial ID

    NCT06877702

    Start Date

    March 19 2025

    End Date

    December 17 2025

    Last Update

    November 17 2025

    Active Locations (2)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (2 locations)

    1

    ICON Lenexa

    Lenexa, Kansas, United States, 66219

    2

    Local Institution - 0002

    Lenexa, Kansas, United States, 66219